Cellectis (ALCLS) - Total Liabilities
Based on the latest financial reports, Cellectis (ALCLS) has total liabilities worth €242.57 Million EUR (≈ $283.59 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cellectis cash flow conversion to assess how effectively this company generates cash.
Cellectis - Total Liabilities Trend (2002–2024)
This chart illustrates how Cellectis's total liabilities have evolved over time, based on quarterly financial data. Check ALCLS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Cellectis Competitors by Total Liabilities
The table below lists competitors of Cellectis ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Omega Flex Inc
NASDAQ:OFLX
|
USA | $19.74 Million |
|
West Wits Mining Ltd
AU:WWI
|
Australia | AU$22.12 Million |
|
Protara Therapeutics Inc
NASDAQ:TARA
|
USA | $13.06 Million |
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
Taiwan | NT$3.07 Billion |
|
FVCBankcorp Inc
NASDAQ:FVCB
|
USA | $2.04 Billion |
|
Idun Industrier AB Series B
ST:IDUN-B
|
Sweden | Skr1.47 Billion |
|
Sonda S.A
SN:SONDA
|
Chile | CL$874.02 Billion |
|
Oak Valley Bancorp
NASDAQ:OVLY
|
USA | $1.82 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Cellectis's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cellectis market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.29 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectis's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectis (2002–2024)
The table below shows the annual total liabilities of Cellectis from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €252.51 Million ≈ $295.21 Million |
+1.18% |
| 2023-12-31 | €249.57 Million ≈ $291.78 Million |
+84.49% |
| 2022-12-31 | €135.28 Million ≈ $158.15 Million |
-7.09% |
| 2021-12-31 | €145.60 Million ≈ $170.22 Million |
-9.35% |
| 2020-12-31 | €160.62 Million ≈ $187.79 Million |
+43.42% |
| 2019-12-31 | €112.00 Million ≈ $130.94 Million |
+121.48% |
| 2018-12-31 | €50.57 Million ≈ $59.12 Million |
+7.64% |
| 2017-12-31 | €46.98 Million ≈ $54.92 Million |
-17.05% |
| 2016-12-31 | €56.63 Million ≈ $66.21 Million |
-33.11% |
| 2015-12-31 | €84.67 Million ≈ $98.99 Million |
-10.83% |
| 2014-12-31 | €94.95 Million ≈ $111.01 Million |
+153.46% |
| 2013-12-31 | €37.46 Million ≈ $43.80 Million |
+12.10% |
| 2012-12-31 | €33.42 Million ≈ $39.07 Million |
-64.77% |
| 2011-12-31 | €94.86 Million ≈ $110.91 Million |
+396.58% |
| 2010-12-31 | €19.10 Million ≈ $22.33 Million |
+5.44% |
| 2009-12-31 | €18.12 Million ≈ $21.18 Million |
+23.92% |
| 2008-12-31 | €14.62 Million ≈ $17.09 Million |
+41.54% |
| 2007-12-31 | €10.33 Million ≈ $12.08 Million |
+99.77% |
| 2006-12-31 | €5.17 Million ≈ $6.05 Million |
+21.87% |
| 2005-12-31 | €4.24 Million ≈ $4.96 Million |
+144.84% |
| 2004-12-31 | €1.73 Million ≈ $2.03 Million |
+37.76% |
| 2003-12-31 | €1.26 Million ≈ $1.47 Million |
-3.16% |
| 2002-12-31 | €1.30 Million ≈ $1.52 Million |
-- |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell p… Read more